Top-News
Freitag,
04.06.2021 21:40
von
PR Newswire
| Aufrufe: 147
Monteverde & Associates PC Filed A Class Action Lawsuit On Behalf Of Shareholders Of GW Pharmaceuticals, PLC In The Southern District Of California
Der Test einer Laborprobe. (Symbolbild)
© alvarez / E+ / Getty Images
http://www.gettyimages.de
PR Newswire
NEW YORK, June 4, 2021
NEW YORK, June 4, 2021 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Southern District of California, Ziegler v. GW Pharmaceuticals, PLC et al, Docket No. 3:21-cv-01019, on behalf of holders of American Depositary Shares of GW Pharmaceuticals, PLC, ("GW" or the "Company") (Nasdaq: GWPH) who held GW securities as of the record date, March 10, 2021 (the "Class Period"), and have been harmed by GW's and its board of directors' alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") regarding the acquisition of GW (the "Merger") by Jazz Pharmaceuticals, PLC (Nasdaq: JAZZ).
On May 5, 2021, each GW ADS was canceled and converted into $200 in cash and 0.120360 Jazz Ordinary Shares (the "Merger Consideration"). The complaint alleges that the Merger Consideration harmed GW shareholders by providing them with less than the inherent value of the Company and that the Proxy Statement GW filed with the U.S. Securities and Exchange Commission to solicit shareholder approval of the Merger misled shareholders about the Company's financials and the Merger in violation of the Exchange Act.
If you wish to serve as lead plaintiff for the class, you must move the Court no later than August 3, 2021. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Click here for more information: http://monteverdelaw.com/case/gw-pharmaceuticals-plc. It is free and there is no cost or obligation to you.
Monteverde & Associates PC is a national class action securities and consumer litigation law firm that has recovered millions of dollars for shareholders and is committed to protecting investors and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017- 2019 an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017- 2020 Top Rated Lawyer.
Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave, Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341
ARIVA.DE Börsen-Geflüster
Werbung
Weiter aufwärts?
| Kurzfristig positionieren in Jazz Pharmaceuticals | ||
|
ME2X7G
| Ask: 1,23 | Hebel: 4,14 |
| mit moderatem Hebel |
Zum Produkt
| |
Morgan Stanley
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: ME2X7G,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Kurse
 |
 |
Attorney Advertising. (C) 2021 Monteverde & Associates PC. Prior results do not guarantee a similar outcome with respect to any future matter.
View original content to download multimedia:http://www.prnewswire.com/news-releases/monteverde--associates-pc-filed-a-class-action-lawsuit-on-behalf-of-shareholders-of-gw-pharmaceuticals-plc-in-the-southern-district-of-california-301306240.html
SOURCE Monteverde & Associates PC
Werbung
Mehr Nachrichten zur GW Pharmaceuticals Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
